“We are excited to add the Chemotherapy Foundation Symposium to the rich offerings in our continuing education portfolio at PER and to our broader oncology-focused enterprises," said MJH Chairman and CEO Michael J. Hennessy Sr.
PLAINSBORO, N.J. (PRWEB) May 20, 2015
PER Events, LLC, an affiliate of accredited medical education provider Physicians’ Education Resource®, (PER®), today announced its acquisition of the renowned multi-tumor cancer conference, the Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow®. This acquisition combines the legacy of one of the largest oncology/hematology conferences with PER’s expanding portfolio of educational meetings to keep oncologists and their practices up-to-date on the latest advances in cancer treatment.
The acquisition deepens the commitment of Michael J. Hennessy Associates, Inc. (MJH), corporate parent of PER, to advancing cancer care through a broad range of educational, research and communications services for the oncology community.
“We are excited to add the Chemotherapy Foundation Symposium to the rich offerings in our continuing education portfolio at Physicians’ Education Resource and to our broader oncology-focused enterprises serving cancer patients, cancer centers, advocacy groups, healthcare providers and caregivers all over the world,” said MJH Chairman and CEO Michael J. Hennessy Sr.
Every year the Chemotherapy Foundation Symposium, the premier gathering of oncologists in the Northeast, updates approximately 2,000 oncologists, oncology nurses, pharmacists and other healthcare professionals on the latest developments across a wide range of therapeutic categories and tumor types. This year’s symposium, to be held Nov. 4-6 in New York City, will retain its educational focus on new developments in cancer therapeutics. The symposium will also provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials and emerging developments that define current progress aimed at the goal of control and cure of cancer.
“The addition of this historic symposium enhances PER’s ability to deliver on our commitment to advancing cancer care through professional education,” said Phil Talamo, vice president, independent medical education and operations at PER. “With the Chemotherapy Foundation Symposium’s focus on ‘Innovative Cancer Therapy for Tomorrow,’ this well-attended conference will improve outcomes for thousands of cancer patients each year by educating oncologists on state-of-the-art care.”
PER provides high-quality live and online education featuring leading national and international faculty. Continuing education activities from PER enable healthcare providers to bring breakthroughs to their practices and their patients quickly by educating them on advances and updates to standards of care in both treatment and disease management.
“Widening the Chemotherapy Foundation’s information network through PER’s national and international oncology meetings will give additional impetus to our already established international presence,” said conference co-chair Dr. Franco Muggia. “We look forward to PER building on the exceptional legacy of Jaclyn Silverman, our conference management director since the Chemotherapy Foundation Symposium’s inception.”
The conference’s other co-chair, Dr. Edward Ambinder, agrees. “Since 1972, the Chemotherapy Foundation Symposium, which was founded by Dr. Ezra Greenspan and presented in association with the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute, has been educating all types of academic, community and international oncologists about the latest information on cancer care, including therapies, information technology and governmental regulation. With PER taking ownership of the Chemotherapy Foundation Symposium beginning this year, we will all benefit from its medical meeting management skills, novel educational tools, time-tested formats and excellent medical speakers.”
The Chemotherapy Foundation Symposium is just the most recent addition to MJH’s portfolio in the cancer field. MJH continues to expand its Strategic Alliance Partnership (SAP) program, which teams the acclaimed OncLive (http://www.OncLive.com) platform of resources for the practicing oncologist with 44 leading cancer centers, most of which are recognized by the National Cancer Institute, nursing schools and physician groups. OncLive’s offerings include the renowned Peer Exchange and OncInsights™ video series; OncLive News Network™, which provides the latest in breaking news on a 24/7 basis, and a full suite of monthly and quarterly publications which includes OncologyLive, Oncology & Biotech News, Oncology Nursing News, Urologists in Cancer Care, Oncology Business Management and Contemporary Oncology. OncLive is also the official communications partner of PER.
Last year, MJH acquired CURE Media Group (http://www.CureToday.com), including its flagship product, CURE™ magazine, the indispensable guide to every stage of the cancer experience. With nearly 1 million readers, CURE is the largest consumer publication in the United States focused entirely on cancer, with the broadest distribution in the industry to cancer patients and caregivers, cancer centers, oncology professionals and advocacy groups. Through its website, live events, resource guide for the newly diagnosed, the Extraordinary Healer™ national nursing award, publications and other books and online tools, CURE Media Group combines science and humanity to make cancer understandable.
Accredited by the Accreditation Council for Continuing Medical Education, PER is the “go-to” resource for live and online activities focusing on oncology and hematology. PER provides high quality, evidence-based CME-certified activities featuring leading national and international faculty with a focus on practice-changing advances and standards of care in treatment and disease management. These activities also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection and practice management. PER serves the oncology healthcare community, including physicians, nurses, nurse practitioners, physician assistants and pharmacists. PER is part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH) family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.
About the Chemotherapy Foundation
The Chemotherapy Foundation is a 501(c)(3) tax-exempt nonprofit organization founded in 1968 and dedicated to the control, cure, and prevention of cancer through innovative medical therapies. The Foundation provides crucial seed money to gifted researchers at institutions in the greater New York City area to start groundbreaking work designed to facilitate breakthrough science. By combining aggressive research with professional education and implementation, the Foundation’s programs are widely recognized in oncology for their significant contributions to improved patient care, disease management and survival. Learn more at http://chemotherapyfoundation.org/.
Media Contacts for PER:
Becky Taylor, 609-240-6886, email@example.com
Robert Walker, 609-378-3730, firstname.lastname@example.org